Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfur hexafluoride is an inert, inorganic gas that functions as an ultrasound contrast agent. It is formulated into microbubbles, typically with a phospholipid shell, which are administered as a suspension. These microbubbles enhance the echogenicity of blood and fluids, thereby improving the signal-to-noise ratio and visualization of anatomical structures during ultrasound examinations. It is used for diagnostic purposes in various applications, including echocardiography to improve the delineation of cardiac chambers and left ventricular endocardial borders, diagnostic assessment of vessels (such as cerebral, carotid, peripheral, liver, and breast vessels), and for evaluating suspected or known vesicoureteral reflux in pediatric patients. The drug is developed and manufactured by Bracco.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfur hexafluoride.